Literature DB >> 22543453

Smooth muscle actin expression in primary bone tumours.

F Hemingway1, T G Kashima, G Mahendra, A Dhongre, P C W Hogendoorn, F Mertens, N A Athanasou.   

Abstract

Alpha isoform of smooth muscle actin (SMA) expression has been reported in giant cell tumour of bone (GCTB) and other benign and malignant bone tumours, but the pattern of SMA expression and the precise nature of SMA-expressing cells in these lesions is uncertain. We determined by immunohistochemistry the expression of SMA and other muscle and vascular markers in normal bone, GCTB and a wide range of primary benign and malignant bone tumours. Cultured stromal cells of GCTB, chondroblastoma (CB), and aneurysmal bone cyst (ABC) were also analysed for SMA expression. SMA was only noted in blood vessels in normal bone. SMA was expressed by mononuclear stromal cells (MSC) cultured from GCTB, ABC and CB. SMA was strongly and diffusely expressed by MSC in non-ossifying fibroma, fibrous dysplasia, and "brown tumour" of hyperparathyroidism. SMA expression was also noted in GCTB, ABC, CB, chondromyxoid fibroma, malignant fibrous histiocytoma of bone and osteosarcoma. Little or no SMA was noted in Langerhans cell histiocytosis, simple bone cyst, Ewing's sarcoma, osteoblastoma, osteoid osteoma, enchondroma, osteochondroma, chondrosarcoma, myeloma, lymphoma, chordoma and adamantinoma. Our findings show that there is differential SMA expression in primary bone tumours and that identifying the presence or absence of SMA is useful in the differential diagnosis of these lesions. The nature of SMA-expressing cells in bone tumours is uncertain but they are negative for desmin and caldesmon and could represent either myofibroblasts or perivascular cells, such as pericytes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22543453     DOI: 10.1007/s00428-012-1235-x

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  39 in total

Review 1.  The myofibroblast: an assessment of controversial issues and a definition useful in diagnosis and research.

Authors:  B Eyden
Journal:  Ultrastruct Pathol       Date:  2001 Jan-Feb       Impact factor: 1.094

2.  Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue.

Authors:  Yu Sin Lau; Afsaneh Sabokbar; C L M H Gibbons; Henk Giele; Nicholas Athanasou
Journal:  Hum Pathol       Date:  2005-09       Impact factor: 3.466

3.  A perivascular origin for mesenchymal stem cells in multiple human organs.

Authors:  Mihaela Crisan; Solomon Yap; Louis Casteilla; Chien-Wen Chen; Mirko Corselli; Tea Soon Park; Gabriella Andriolo; Bin Sun; Bo Zheng; Li Zhang; Cyrille Norotte; Pang-Ning Teng; Jeremy Traas; Rebecca Schugar; Bridget M Deasy; Stephen Badylak; Hans-Jörg Buhring; Jean-Paul Giacobino; Lorenza Lazzari; Johnny Huard; Bruno Péault
Journal:  Cell Stem Cell       Date:  2008-09-11       Impact factor: 24.633

4.  Giant cell tumor of bone. Variations in patterns of appearance of different cell types.

Authors:  T Aparisi; B Arborgh; J L Ericsson
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1979-02-09

5.  Alpha-smooth muscle actin is expressed in a subset of bone marrow stromal cells in normal and pathological conditions.

Authors:  A Schmitt-Gräff; O Skalli; G Gabbiani
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1989

6.  Central giant cell granulomas of the jaws: phenotype and proliferation-associated markers.

Authors:  M O'Malley; M A Pogrel; J C Stewart; R G Silva; J A Regezi
Journal:  J Oral Pathol Med       Date:  1997-04       Impact factor: 4.253

7.  Expression of smooth muscle actin in osteoblasts in human bone.

Authors:  B Kinner; M Spector
Journal:  J Orthop Res       Date:  2002-05       Impact factor: 3.494

8.  Histological and immunohistochemical diversities, and proliferative activity and grading in osteosarcomas.

Authors:  T Hasegawa; T Hirose; K Seki; K Hizawa; S Ishii; J Wakabayashi
Journal:  Cancer Detect Prev       Date:  1997

9.  Giant cell tumor of the skin: a morphologic and immunohistochemical study of five cases.

Authors:  Mai P Hoang; Beverly B Rogers; Jorge Albores-Saavedra
Journal:  Ann Diagn Pathol       Date:  2002-10       Impact factor: 2.090

10.  Clinical and immunohistochemical characteristics of benign giant cell tumour of bone with pulmonary metastases: case series.

Authors:  S Osaka; H Sugita; E Osaka; Y Yoshida; J Ryu; A Hemmi; K Suzuki
Journal:  J Orthop Surg (Hong Kong)       Date:  2004-06       Impact factor: 1.118

View more
  9 in total

Review 1.  Pericytes in sarcomas of bone.

Authors:  Le Chang; Vi Nguyen; Alan Nguyen; Michelle A Scott; Aaron W James
Journal:  Med Oncol       Date:  2015-06-16       Impact factor: 3.064

Review 2.  The clinical approach toward giant cell tumor of bone.

Authors:  Lizz van der Heijden; P D Sander Dijkstra; Michiel A J van de Sande; Judith R Kroep; Remi A Nout; Carla S P van Rijswijk; Judith V M G Bovée; Pancras C W Hogendoorn; Hans Gelderblom
Journal:  Oncologist       Date:  2014-04-09

3.  A diagnosis of giant cell-rich tumour of bone is supported by p63 immunohistochemistry, when more than 50 % of cells is stained.

Authors:  André Maues De Paula; Alexandre Vasiljevic; Roch Giorgi; Anne Gomez-Brouchet; Sébastien Aubert; Xavier Leroy; Hélène Duval; Gonzague de Pinieux; Corinne Bouvier
Journal:  Virchows Arch       Date:  2014-08-07       Impact factor: 4.064

Review 4.  A review of primary osteosarcoma of the larynx and case report.

Authors:  Esraa Mosalleum; Amir Afrogheh; Sacha Stofberg; Abraham Fourie Bezuidenhout; Johann Schneider; Jos Hille
Journal:  Head Neck Pathol       Date:  2014-06-20

5.  Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype.

Authors:  Ruben A L de Groen; Ronald van Eijk; Stefan Böhringer; Tom van Wezel; Richard Raghoo; Dina Ruano; Patty M Jansen; Inge Briaire-de Bruijn; Fleur A de Groot; Karin Kleiverda; Liane Te Boome; Valeska Terpstra; Henriette Levenga; Alina Nicolae; Eduardus F M Posthuma; Isabelle Focke-Snieders; Lizan Hardi; Wietske C E den Hartog; Lara H Bohmer; Pancras C W Hogendoorn; Anke van den Berg; Arjan Diepstra; Marcel Nijland; Pieternella J Lugtenburg; Marie José Kersten; Steven T Pals; Hendrik Veelken; Judith V M G Bovée; Arjen H G Cleven; Joost S P Vermaat
Journal:  Blood Adv       Date:  2021-10-12

6.  Biological characterization of preclinical Bioluminescent Osteosarcoma Orthotopic Mouse (BOOM) model: A multi-modality approach.

Authors:  Rama Garimella; Jeff Eskew; Priyanka Bhamidi; George Vielhauer; Yan Hong; H Clarke Anderson; Ossama Tawfik; Peter Rowe
Journal:  J Bone Oncol       Date:  2013-02       Impact factor: 4.072

7.  Prognostic impact of reduced connexin43 expression and gap junction coupling of neoplastic stromal cells in giant cell tumor of bone.

Authors:  Peter Balla; Mate Elod Maros; Gabor Barna; Imre Antal; Gergo Papp; Zoltan Sapi; Nicholas Anthony Athanasou; Maria Serena Benassi; Pierro Picci; Tibor Krenacs
Journal:  PLoS One       Date:  2015-05-01       Impact factor: 3.240

8.  Spontaneous extraskeletal osteosarcoma with various histological growth patterns in the abdominal wall of an ICR mouse.

Authors:  Tsuyoshi Ito; Yoshitaka Katoh; Yuko Shimada; Aya Ohnuma-Koyama; Naofumi Takahashi; Maki Kuwahara; Takanori Harada
Journal:  J Toxicol Pathol       Date:  2015-10-05       Impact factor: 1.628

9.  Histone Deacetylase Inhibitors as a Therapeutic Strategy to Eliminate Neoplastic "Stromal" Cells from Giant Cell Tumors of Bone.

Authors:  Sanne Venneker; Robin van Eenige; Alwine B Kruisselbrink; Ieva Palubeckaitė; Alice E Taliento; Inge H Briaire-de Bruijn; Pancras C W Hogendoorn; Michiel A J van de Sande; Hans Gelderblom; Hailiang Mei; Judith V M G Bovée; Karoly Szuhai
Journal:  Cancers (Basel)       Date:  2022-09-27       Impact factor: 6.575

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.